TP53 and neoplasm: However, disagreements remain concerning the underlying mechanism, because the sensitivity of certain tumor cell lines does not appear to be correlated with either p53 status or MetAP2 inhibition [31], as p53 is mutated in over 50% of human tumors [32] displaying different degrees of sensitivity to fumagillin.